Lisa Ferguson‐Sells

Safety, Tolerability, and Effects on Plasma and Cerebrospinal Fluid Amyloid-β After Inhibition of γ-Secretase

Eric Siemers, Robert A. Dean, Stuart Friedrich et al. · Clinical Neuropharmacology · 2007 · 153 citations

Medicine, Neurology, Pharmacology +16

Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of the Amyloid β Monoclonal Antibody Solanezumab in Japanese and White Patients With Mild to Moderate Alzheimer Disease

Kazunori Uenaka, Masako Nakano, Brian A. Willis et al. · Clinical Neuropharmacology · 2011 · 42 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID‐19 Infection

Emmanuel Chigutsa, Lisa M. O’Brien, Lisa Ferguson‐Sells et al. · Clinical Pharmacology & Therapeutics · 2021 · 40 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia

Brian A. Willis, Karen Sundell, D. Richard Lachno et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 2018 · 35 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension: A multiple ascending‐dose study

David S. Small, Lisa Ferguson‐Sells, Nagib Dahdah et al. · British Journal of Clinical Pharmacology · 2019 · 12 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16